Statements (39)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:approvedBy |
2003
|
| gptkbp:ATCCode |
J05AE08
|
| gptkbp:bioavailability |
60% (oral)
|
| gptkbp:CASNumber |
gptkb:163706-06-7
|
| gptkbp:contraindication |
severe hepatic impairment
concurrent use with certain drugs (e.g., rifampin) |
| gptkbp:eliminationHalfLife |
6-7 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasInChIKey |
XJXATXFEYFJXQX-GXFFZTMASA-N
|
| gptkbp:hasMolecularFormula |
C38H52N6O7
|
| gptkbp:hasSMILES |
CC(C)[C@@H](C(=O)N1CCCC1(Cc2ccccc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N(C)C)NC(=O)OC(C)(C)C
|
| gptkbp:hasUNII |
83T1F4QUIM
|
| https://www.w3.org/2000/01/rdf-schema#label |
163706-06-7
|
| gptkbp:IUPACName |
N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-2-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]pyrrolidine-2-carboxamide
|
| gptkbp:legalStatus |
prescription only
patent expired in US (2022) |
| gptkbp:listedOn |
gptkb:WHO_Model_List_of_Essential_Medicines
|
| gptkbp:marketedAs |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:mechanismOfAction |
HIV-1 protease inhibitor
|
| gptkbp:meltingPoint |
205-207°C
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:molecularWeight |
704.9 g/mol
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:PubChem_CID |
148192
CHEMBL933 DB01072 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache jaundice rash hyperbilirubinemia |
| gptkbp:synonym |
gptkb:Atazanavir
|
| gptkbp:usedFor |
HIV infection
antiviral drug |
| gptkbp:bfsParent |
gptkb:AR-C
|
| gptkbp:bfsLayer |
6
|